Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Granted Continued Listing on Nasdaq

NEW YORK, June 28 (GenomeWeb News) - Sequenom has received a letter from Nasdaq's Listing Qualifications Panel stating that it is now compliant with the minimum bid price requirement for continued listing on the Nasdaq National Market, Sequenom said today.


The panel has also granted Sequenom an exception until August 15 to file its 10-Q with the Securities and Exchange Commission for the quarter ending June 30, 2006, evidencing shareholders' equity of at least $10 million, the company said.


According to Sequenom, the panel also acknowledged that the company met the requirement based on net proceeds from its $33 million stock placement last month.


In May, the firm received a letter from Nasdaq notifying it that it was not compliant with the stockholder equity listing requirement. Sequenom subsequently implemented a reverse stock split in an effort to regain Nasdaq compliance, along with the private stock sale.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.